Dr. Andrea Apolo On Avelumab and its Effect on Locally Advanced or Metastatic Urothelial Carcinoma
Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses promising treatment methods for patients with refractory, metastatic urothelial carcinoma.
Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses promising treatment methods for patients with refractory, metastatic urothelial carcinoma.
The anti-PD-L1 antibody avelumab has shown promising results in refractory, metastatic urothelial carcinoma. The checkpoint inhibitor had clinical activity, showing tumor shrinkage, says Apollo. There is no data yet regarding overall survival, but durable responses have been observed. This development is exciting for bladder cancer research, Apolo adds.
Next steps in the research include studying the agent in large clinical trials. These studies include identifying biomarkers and investigating potential combination therapies, Apolo says.
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
